AUPH (Aurinia Pharmaceuticals) Total Liabilities: $156.4 Mil (As of Mar. 2026)

What is Aurinia Pharmaceuticals Total Liabilities?

Aurinia Pharmaceuticals AUPH -1.14% 81 Total Liabilities is $156.4 Mil as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.00 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Aurinia Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $156.4 Mil.

Aurinia Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 ($161.76 Mil) to Dec. 2025 ($170.26 Mil) but then declined from Dec. 2025 ($170.26 Mil) to Mar. 2026 ($156.37 Mil).

Aurinia Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 ($170.11 Mil) to Dec. 2024 ($173.17 Mil) but then declined from Dec. 2024 ($173.17 Mil) to Dec. 2025 ($170.26 Mil).

Aurinia Pharmaceuticals Total Liabilities Related Terms

Aurinia Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Total Liabilities Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

64.28

65.43

170.11

173.17

170.26

Aurinia Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															154.66	167.26	161.76	170.26	156.37

81GF Score

Aurinia Pharmaceuticals Inc AUPH

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aurinia Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aurinia Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	93.724	+	(57.222	+	6.662
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	12.648	+	0	+	0)
	=	170.3

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	751.587	-	581.331
	=	170.3

Aurinia Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	86.556	+	(50.499	+	6.903
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	12.413	+	0	+	0)
	=	156.4

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	723.997	-	567.626
	=	156.4

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $156.4 Mil mean?

Aurinia Pharmaceuticals (AUPH) has a Total Liabilities of $156.4 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aurinia Pharmaceuticals and its competitors.

Is Aurinia Pharmaceuticals' Total Liabilities too high?

Aurinia Pharmaceuticals' current Total Liabilities is $156.4 Mil. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aurinia Pharmaceuticals' Total Liabilities compare to KOD and ABCL?

Aurinia Pharmaceuticals' Total Liabilities of $156.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Total Liabilities is $156.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aurinia Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.00, compared to a current price of $15.61 — trading 11.5% above its estimated fair value. The current Total Liabilities is $156.4 Mil. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Total Liabilities is $156.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.61 is trading 11.5% above its estimated GF Value™ of $14.00. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

Total Liabilities: $156.4 Mil
GF Value™: $14.00 vs. price of $15.61 (11.5% above fair value)
GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies KOD ABCL AGIO IMNM OCUL NKTR PVLA GENB SLBT NTLA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IKAP:Germany

Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

81GF Score

Get the complete analysis for AUPH

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.61

Price

$14.00

GF Value

View AUPH Analysis

See Total Liabilities data for all stocks →